US President Donald Trump has announced a landmark deal with drugmakers Novo Nordisk and Eli Lilly, set to significantly reduce the price of hugely popular obesity drugs for millions of Americans. The agreement, unveiled at the White House, will slash costs for injectable treatments like Wegovy and Zepbound, as well as two forthcoming oral medications. The deal aims to save…
Tag: wegovy
-
GLP-1 Drugs Lower Cancer Rates in Weight Loss Study
New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient’s risk of developing certain cancers. This is mainly for the better. A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists – such as Ozempic, Wegovy, Mounjaro, and Zepbound –…
-
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Danish pharmaceutical giant Novo Nordisk, which rode a wave of unprecedented success with its weight-loss drug Wegovy, has announced a global hiring freeze for non-critical roles. This signals a dramatic shift from rapid expansion to rigorous cost-cutting. Sales begin to slow and competition intensifies. Novo Nordisk’s hiring freeze is a significant turn for the company. The Wegovy Hiring Spree The…
-
Healthcare Costs Rise with Ozempic and Wegovy
A new study has found that while weight-loss drugs like Ozempic and Wegovy significantly improve health, they are also linked to a sustained increase in spending on other medical care. The study, led by Yale economics professor Jason Abaluck and published in JAMA Network Open, confirms that semaglutide (the active ingredient in Wegovy and Ozempic) effectively reduces weight, blood pressure,…
-
Weight-Loss Drug Costs Fuel US Employer Healthcare Cuts
More than half of large employers in the United States are planning to reduce their healthcare benefits in 2026. This decision comes as the skyrocketing cost of new weight-loss and specialty medicines puts unprecedented pressure on budgets. The soaring costs of weight-loss drugs are a key concern, according to a new survey. The report, released on Wednesday by consulting firm…
-
Ozempic and Mounjaro are reshaping South Africa’s health market
The landscape of weight management and diabetes treatment in South Africa is undergoing a dramatic transformation. This change is driven by the meteoric rise in popularity of a class of drugs known as GLP-1s, including Ozempic and Mounjaro. These medications, initially developed for Type 2 diabetes, have shown significant efficacy in promoting weight loss. As a result, there is unprecedented…
-
GLP-1 drugs increase healthcare costs for obese patients
GLP-1 drugs, such as Novo Nordisk’s Wegovy, have become popular for weight loss among US patients struggling with obesity. Despite significant weight-loss benefits, an analysis of US health insurance claims reveals that these medications may drive healthcare costs higher rather than reducing obesity-related expenses. According to data from Prime Therapeutics, a pharmacy benefits manager, US patients’ average annual medical expenses…
-
As competition heats up, Novo Nordisk’s share price declines
Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…
-
Low long-term adherence to weight loss drugs
A recent analysis of US pharmacy claims has revealed that only one in four patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss continued using the medications two years later. The study, which provides a comprehensive view of real-world patient experiences, showed a steady decline in usage over time. The analysis, conducted by Prime Therapeutics and Magellan Rx Management,…